| Category | Details |
| Definition | Muscular dystonia is a movement disorder characterized by sustained or intermittent involuntary muscle contractions causing abnormal postures and movements. |
| Global Epidemiology | – Estimated 300,000 individuals affected globally. |
| – Third most common movement disorder after Parkinson’s disease and tremors. |
| – Frequently misdiagnosed, with diagnostic delays of 2–10 years in many cases. |
| Prevalence in Key Regions | – United States: ~250,000 cases diagnosed. |
| – European Union: ~500,000 cases (~100 per 100,000 population). |
| – Canada: ~50,000 cases, though gaps in treatment access exist. |
| – Caribbean: Estimated 20,000–25,000 cases with significant unmet healthcare needs. |
| Medicinal Cannabis Approvals | – United States (FDA): No specific approval for dystonia; CBD and THC used off-label for spasticity management. |
| – European Union (EMA): Nabiximols (Sativex) approved in 2010 for MS spasticity; used off-label for dystonia. |
| – Canada: Nabiximols approved for neurological spasticity in 2012; off-label use for dystonia is common. |
| – Australia (TGA): Approved nabiximols for spasticity in 2015; used off-label for dystonia. |
| – Israel: Authorized medical cannabis for movement disorders, including dystonia, since 2013. |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Reduces muscle hyperactivity and spasticity; neuroprotective and anti-inflammatory effects. |
| – THC (Tetrahydrocannabinol): Efficacious for spasticity; psychoactive effects limit widespread use. |
| – CBG (Cannabigerol): Evidence suggests muscle relaxation and neuroprotective properties. |
| – THCV (Tetrahydrocannabivarin): Promising for reducing hyperkinetic movements in preclinical studies. |
| Mechanism of Action | – Modulates CB1 and CB2 receptors in motor control pathways to reduce abnormal muscle contractions. |
| – CBD reduces inflammation and oxidative stress, both contributing to muscle dysfunction in dystonia. |
| Key Clinical Studies | – Consroe et al., 1986: Open-label evaluation demonstrated significant symptom improvement with CBD-enriched therapies. |
| – Pagano et al., 2021: Cannabinoids showed potential for managing hyperkinetic movement disorders, including dystonia. |
| Dosage Guidelines | – Nabiximols (Sativex): Up to 12 sprays/day; each spray contains 2.7 mg THC and 2.5 mg CBD. |
| – Oral CBD: Starting dose 2.5 mg/kg/day; titrate based on patient response. |
| – THC (Inhaled): Starting dose 1–2 mg/day; incremental increases based on tolerance and effect. |
| – CBG/THCV (Experimental): Early trials suggest 5–20 mg/day for hyperkinetic movement reduction. |
| Administration Methods | – Sublingual Spray (Nabiximols): Rapid onset via mucosal absorption; consistent dosing. |
| – Oral Capsules: Controlled dosing with slower onset (60–90 minutes). |
| – Inhalation: Rarely used for dystonia due to unpredictable dosing and psychoactive effects. |
| Adverse Effects | – CBD: Fatigue, diarrhea, appetite changes; rare: elevated liver enzymes. |
| – THC: Anxiety, dizziness, cognitive issues, potential dependence. |
| – Nabiximols: Common side effects: dry mouth, dizziness, fatigue; rare: psychosis. |
| Research Gaps | – Limited long-term safety and efficacy data for cannabinoids like CBG and THCV in dystonia treatment. |
| – Lack of standardized dosing protocols and robust clinical trials for dystonia cannabinoid therapies. |
| Opportunities in the Caribbean | – High Prevalence: 20,000–25,000 cases in the Caribbean with significant unmet healthcare needs. |
| – Specialized Clinics: Developing cannabinoid-focused clinics could address local needs and attract medical tourists. |
| – Research Hub: Regional collaborations could position the Caribbean as a leader in cannabinoid-based dystonia treatment. |
